CentricsBio, Inc.
June 16, 2025
Company Presentation
Immunology
CentricsBio is a biotech venture company established in 2017 and located at South Korea. This company is developing mAb against CD300c on Monocyte. Once this mAb binds into CD300c on Monocyte, the Monocyte can be efficiently differentiated into Macrophage. Also, Macrophage can be further activated and can be developed as anti-cancer (activates CTL) as well as Alzheimer therapeutics (Amyloid beta cleaning). Outstanding In-vivo animal data is now available, and GLP tox is now starting.
Therapeutics against Autoimmune disease is now under development using CD300c antigen-Fc fusion molecule against Atopy and others.
Now CentricsBio is seeking opportunities of “Investment,” “Co-development” and “Licensing.” CentricsBio will be more than happy to discuss those opportunities at BIO use 2025 in Boston.
Company HQ City:
Seoul
Company HQ State:
Seoul
Company HQ Country:
Korea, Republic of
Year Founded:
2017
Lead Product in Development:
CB301, a candidate for solid tumor (colon and lung cancer, melanoma, TNBC, etc)
CB201, a candidate for Alzheimer's disease, dementia, etc
CEO
Jaewon Jeon, Ph.D
Development Phase of Lead Product
Pre-Clinical
What is your next catalyst (value inflection) update?
Approximately Jul 2025, entry to non-clinical phase
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}